
Can Silicon Valley Find Christianity?
Silicon Valley, it seems, is coming to Jesus. There are no bad conversions, in my book; I was born and raised a Christian and remain one, and it's good, from that standpoint, to see erstwhile nonbelievers take an interest in the faith, whatever the reason.
Thus, I was cautiously optimistic as I read a recent Vanity Fair feature, by the writer Zoë Bernard, on emerging tech-world Christianity. 'It was a time not so very long ago, mostly in the 2010s, when Silicon Valley cultivated a stance of pointed hostility not only toward conservatism but to the Protestant doctrines that underpin much of American life,' Bernard writes. But no more. Christianity is now an object of fascination to the libertarian capitalists of the tech world.
In the faith, Bernard writes, the converts of Silicon Valley see a great deal of utility: a source of community and, therefore, professional networking; an index of ethics capable of checking some of the libertine excesses of their world; a signal of self-disciplined seriousness versus the flip-flop-wearing whiz-kid archetype popular in this same universe a mere decade ago. Christianity has become a potential path to fortune.
Bernard's article makes clear that some converts are cynical characters merely pretending at Christianity. 'I guarantee you there are people that are leveraging Christianity to get closer to Peter Thiel,' one entrepreneur told Bernard. But even if a significant proportion of the new believers are entirely sincere, that doesn't mean their theology is copacetic. Christianity, they ought to know, is not a life hack: It's a life-upending surrender to the fact of divine love.
From the February 2025 issue: The army of God comes out of the shadows
American Christianity has a tendency to produce forms of belief and practice that are facially antithetical to Christian teaching. Consider, for example, the purveyors of the prosperity gospel, who promise worldly riches as a reward for moral uprightness. (One adherent has now been appointed the head of a new faith office created by Donald Trump.) Although the prosperity preachers still teach certain core Christian concepts—such as the resurrection of Christ—the overall drift strikes me as self-serving, devoted to money: decidedly unchristian. The emerging variety of techno-libertarian Christianity appears to have faults of a similar type.
Based on Bernard's report, Christianity is gaining ground in Silicon Valley partially because it encourages a kind of orderly behavior that secular liberalism fails to enforce. 'No one wants the Palantir guy to be high on acid for two weeks at Burning Man,' the same venture-capital executive told Bernard. 'You want hard workers. People who are like, 'I learned that at West Point.' We have Israelis who served in the IDF and are religious and conservative and super libertarian. And we're like, 'Yeah, that seems focused. We'll take that.'' Religious faith is a tool for keeping people productive, in other words, a private code of ethics that enforces the kind of activity that lends itself to producing wealth.
In that sense, Silicon Valley Christians perhaps see Christianity as a kind of technology, which is to say a product used to accomplish human purposes. Granted, Christianity promises certain benefits to its adherents, such as inner peace, eternal salvation, the comfort of community, and prosocial ethics. That said, Christianity at its core is not a religion that can reliably deliver socially desirable outcomes, nor is it intended to be. In Matthew 19:21, a disciple asks Jesus how to live as a model Christian, to which 'Jesus said to him, 'If you wish to be perfect, go, sell your possessions, and give the money to the poor, and you will have treasure in heaven; then come, follow me.'' Christianity disrupts life as we know it rather than reinforcing a self-serving status quo. It venerates generations of Christian martyrs whose examples are prized precisely because they placed obedience to God before more advantageous beliefs or activities. The formation of their faith was contingent not on temporal success, but rather on another principle altogether: that Christianity is worth following not because it has the potential to improve one's life, though it can, but rather because it is true.
Alexander C. Karp and Nicholas W. Zamiska: Why Silicon Valley lost its patriotism
This is key, because if Christianity is true—if we really were created to love God and one another and were then rescued from our sins by the sacrificial intervention of Christ—then everything else one believes must flow downstream of that essential reality. Believers' personal philosophies, practices, and politics are all answerable to the Christian religion: There is no domain of life outside God's interest, and he requires that all things be brought in accordance with his will. This means that economics is God's business, which is bad news for techno-libertarians, because Christ's teachings decidedly militate against the rapacious acquisition of wealth. 'No servant can serve two masters, for either he will hate the one and love the other, or he will be devoted to the one and despise the other,' Jesus says. 'You cannot serve God and money.'
There always have been and always will be rival interpretations of what exactly the Christian faith demands of its followers, motivated in many cases by prior commitments. In that sense, the tendency of American Christianity to result in philosophies that advance worldly aims is nothing new. But much of the faith's central traditions run counter to the aspirations of this new Christ-curious class. Christianity is about moving fast and breaking things, but not in the direction the tech Christians seem to have in mind.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Micron to invest $200 billion in US memory facilities
Memory chip maker Micron (MU) announced on Thursday that it will invest an additional $30 billion in the US, as it looks to build out its manufacturing and research and development facilities in Idaho and New York. The move brings Micron's total US manufacturing and R&D investments up to roughly $200 billion which will create some 90,000 direct and indirect jobs, the company said. Micron is receiving about $6.5 billion in funding from the US CHIPS Act. The plans call for Micron to build a second memory manufacturing plant at its Boise, Idaho, facility and a massive chip fabrication complex in New York. The company is also updating and expanding its Virginia plant. Micron also said it expects the second Idaho plant to help it bring its advanced high-bandwidth memory (HBM) manufacturing to the US. HBM is a key component in AI data centers. 'Micron's investment in advanced memory manufacturing and HBM capabilities in the U.S., with support from the Trump Administration, is an important step forward for the AI ecosystem,' Nvidia (NVDA) CEO Jensen Huang said in a statement. 'Micron's leadership in high-performance memory is invaluable to enabling the next generation of AI breakthroughs that NVIDIA is driving. We're excited to collaborate with Micron as we push the boundaries of what's possible in AI and high-performance computing,' Huang added. All totaled, Micron says the investments will allow the company to produce 40% of its DRAM memory in the US. Its initial Idaho plant is expected to begin pumping out the hardware in 2027. Micron also says it is set to begin preparing the ground for its New York facilities later this year. 'This approximately $200 billion investment will reinforce America's technological leadership, create tens of thousands of American jobs across the semiconductor ecosystem and secure a domestic supply of semiconductors—critical to economic and national security,' Micron CEO Sanjay Mehrotra said in a statement. 'We are grateful for the support from President Trump, Secretary Lutnick and our federal, state, and local partners who have been instrumental in advancing domestic semiconductor manufacturing.' Micron isn't the only company bringing HBM production to the US, though. South Korea's SK Hynix is also building a new HBM plant in Indiana as part of a $3.8 billion construction project. The Trump administration, and the Biden administration before it, has made onshoring semiconductor manufacturing a key component of its domestic agenda, as it seeks to wean itself off of the country's dependence on foreign-made chips. Companies ranging from Intel (INTC) and TSMC (TSM) to Samsung and GlobalFounderies (GFS) and others have recently announced plans to build or upgrade their facility throughout the country, thanks in part to billions of dollars in funding through the CHIPS Act. Email Daniel Howley at dhowley@ Follow him on X/Twitter at @DanielHowley. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
20 minutes ago
- Yahoo
BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion
BioNTech will acquire all shares of CureVac after the two sides reached an agreement in a deal valued around $1.25 billion. Each share of CureVac, a clinical-stage biotech company, will be exchanged for about $5.46 in BioNTech American depositary shares. Upon the deal's closing, CureVac shareholders are expected to own between 4% and 6% of the German developer of RNA vaccines and immunotherapies. ICE Raids Have Sent Latino Shoppers Into Hiding and Big Brands Are Hurting The Secret to Retaining the Best Employees: Ask Them These Four Questions Here's How Much Money the U.S. Is Earning From Tariffs, in Charts How Home Depot Became Ground Zero in Trump's Deportation Push Supply Chains Become New Battleground in the Global Trade War BioNTech Chief Executive Ugur Sahin said the plan is to bring complementary capabilities between the two companies together to develop transformative cancer treatments. CureVac's operating subsidiary will become a wholly owned subsidiary of BioNTech following the close of the transaction. As part of this plan, BioNTech will integrate CureVac's research and manufacturing site in Tübingen, Germany. The deal was unanimously approved by both companies' management and supervisory boards. It is expected to close in 2025. Shares of CureVac surged 29% to $5.25 in premarket trading. Write to Denny Jacob at Pulls Outlook as Sales Fall Bojangles Is Exploring a Sale While the Fried-Chicken Market Is Hot Why Bosses Should Give Feedback in the Morning The Audacious Reboot of America's Nuclear Energy Program Muted May Inflation Defies Tariff Fears Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Is Fidelity Select Portfolio Medical Technology and Devices (FSMEX) a Strong Mutual Fund Pick Right Now?
If you have been looking for Sector - Health funds, a place to start could be Fidelity Select Portfolio Medical Technology and Devices (FSMEX). FSMEX has a Zacks Mutual Fund Rank of 1 (Strong Buy), which is based on various forecasting factors like size, cost, and past performance. Zacks categorizes FSMEX as Sector - Health, a segment packed with options. Sector - Health mutual funds offer investors a focus on the healthcare industry, one of the largest sectors in the American economy. These funds can include everything from pharmaceutical companies to medical device manufacturers and for-profit hospitals. Fidelity is responsible for FSMEX, and the company is based out of Boston, MA. Fidelity Select Portfolio Medical Technology and Devices made its debut in April of 1998, and since then, FSMEX has accumulated about $4.48 billion in assets, per the most up-to-date date available. The fund is currently managed by Edward Yoon who has been in charge of the fund since May of 2007. Investors naturally seek funds with strong performance. This fund has delivered a 5-year annualized total return of 5.12%, and it sits in the middle third among its category peers. If you're interested in shorter time frames, do not dismiss looking at the fund's 3 -year annualized total return of 3.37%, which places it in the bottom third during this time-frame. It is important to note that the product's returns may not reflect all its expenses. Any fees not reflected would lower the returns. Total returns do not reflect the fund's [%] sale charge. If sales charges were included, total returns would have been lower. When looking at a fund's performance, it is also important to note the standard deviation of the returns. The lower the standard deviation, the less volatility the fund experiences. Over the past three years, FSMEX's standard deviation comes in at 18.22%, compared to the category average of 15.64%. Over the past 5 years, the standard deviation of the fund is 19.24% compared to the category average of 16.64%. This makes the fund more volatile than its peers over the past half-decade. Investors should note that the fund has a 5-year beta of 0.92, which means it is hypothetically less volatile than the market at large. Alpha is an additional metric to take into consideration, since it represents a portfolio's performance on a risk-adjusted basis relative to a benchmark, which in this case, is the S&P 500. With a negative alpha of -7.95, managers in this portfolio find it difficult to pick securities that generate better-than-benchmark returns. Costs are increasingly important for mutual fund investing, and particularly as competition heats up in this market. And all things being equal, a lower cost product will outperform its otherwise identical counterpart, so taking a closer look at these metrics is key for investors. In terms of fees, FSMEX is a no load fund. It has an expense ratio of 0.63% compared to the category average of 1.11%. Looking at the fund from a cost perspective, FSMEX is actually cheaper than its peers. While the minimum initial investment for the product is $0, investors should also note that there is no minimum for each subsequent investment. Fees charged by investment advisors have not been taken into considiration. Returns would be less if those were included. Overall, Fidelity Select Portfolio Medical Technology and Devices ( FSMEX ) has a high Zacks Mutual Fund rank, and in conjunction with its comparatively similar performance, average downside risk, and lower fees, Fidelity Select Portfolio Medical Technology and Devices ( FSMEX ) looks like a great potential choice for investors right now. Your research on the Sector - Health segment doesn't have to stop here. You can check out all the great mutual fund tools we have to offer by going to to see the additional features we offer as well for additional information. For analysis of the rest of your portfolio, make sure to visit for our full suite of tools which will help you investigate all of your stocks and funds in one place. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Get Your Free (FSMEX): Fund Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data